heart failure

News

AZ's Q3 results disappoint - but COVID-19 vaccine trial is s...

AstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely watched coronavirus vaccine trial.

News

Boehringer, Yale trial digital tech in heart failure

Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects.

News

Amgen shares down as heart failure drug disappoints in phase...

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.

News

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi

News

FDA grants fast review for Bayer/Merck & Co's heart failure ...

The FDA has granted a faster Priority Review for Bayer and Merck & Co’s filing for vericiguat, which is being developed for chronic heart failure with reduced ejection fraction, followi

News

FDA approves new heart failure use for AZ's Farxiga

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fract

AZ's Q3 results disappoint - but COVID-19 vaccine trial is s...

Boehringer, Yale trial digital tech in heart failure

Amgen shares down as heart failure drug disappoints in phase...

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

FDA grants fast review for Bayer/Merck & Co's heart failure ...

FDA approves new heart failure use for AZ's Farxiga

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

heart failure

Editor's Picks